Cargando…

Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option

Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these n...

Descripción completa

Detalles Bibliográficos
Autores principales: Argentiero, Antonella, Calabrese, Angela, Sciacovelli, Angela Monica, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Brunetti, Oronzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569435/
https://www.ncbi.nlm.nih.gov/pubmed/33102398
http://dx.doi.org/10.1155/2020/8679751
_version_ 1783596731026374656
author Argentiero, Antonella
Calabrese, Angela
Sciacovelli, Angela Monica
Delcuratolo, Sabina
Solimando, Antonio Giovanni
Brunetti, Oronzo
author_facet Argentiero, Antonella
Calabrese, Angela
Sciacovelli, Angela Monica
Delcuratolo, Sabina
Solimando, Antonio Giovanni
Brunetti, Oronzo
author_sort Argentiero, Antonella
collection PubMed
description Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor. What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we reported a case of a patient with PDAC of the head with multiple liver metastases, who underwent first-line chemotherapy with mFOLFIRINOX. After 10 cycles, he achieved a complete radiological response of liver metastases and a partial response of pancreatic lesion. A duodenocephalopancreasectomy was performed. Due to liver a lung metastases after 8 months from surgery, a second-line therapy was started with a disease-free survival and overall survival of 8 months and 45 months, respectively. Improvement in the molecular characterization of PDAC could help in the selection of patients suitable for multimodal treatments. This trial is registered with NCT02892305 and NCT00855634.
format Online
Article
Text
id pubmed-7569435
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-75694352020-10-22 Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option Argentiero, Antonella Calabrese, Angela Sciacovelli, Angela Monica Delcuratolo, Sabina Solimando, Antonio Giovanni Brunetti, Oronzo Can J Gastroenterol Hepatol Research Article Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor. What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we reported a case of a patient with PDAC of the head with multiple liver metastases, who underwent first-line chemotherapy with mFOLFIRINOX. After 10 cycles, he achieved a complete radiological response of liver metastases and a partial response of pancreatic lesion. A duodenocephalopancreasectomy was performed. Due to liver a lung metastases after 8 months from surgery, a second-line therapy was started with a disease-free survival and overall survival of 8 months and 45 months, respectively. Improvement in the molecular characterization of PDAC could help in the selection of patients suitable for multimodal treatments. This trial is registered with NCT02892305 and NCT00855634. Hindawi 2020-10-09 /pmc/articles/PMC7569435/ /pubmed/33102398 http://dx.doi.org/10.1155/2020/8679751 Text en Copyright © 2020 Antonella Argentiero et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Argentiero, Antonella
Calabrese, Angela
Sciacovelli, Angela Monica
Delcuratolo, Sabina
Solimando, Antonio Giovanni
Brunetti, Oronzo
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
title Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
title_full Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
title_fullStr Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
title_full_unstemmed Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
title_short Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
title_sort complete response of synchronous liver metastasis in a pancreatic ductal adenocarcinoma, when surgery could represent a therapeutic option
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569435/
https://www.ncbi.nlm.nih.gov/pubmed/33102398
http://dx.doi.org/10.1155/2020/8679751
work_keys_str_mv AT argentieroantonella completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption
AT calabreseangela completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption
AT sciacovelliangelamonica completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption
AT delcuratolosabina completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption
AT solimandoantoniogiovanni completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption
AT brunettioronzo completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption